13F Holdings
中文EN

RVRC Revium Rx.

Pharmaceutical Preparations · OTC · SEC CIK 1839140 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA—
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets22.4%
Debt / equity0.00x
Current ratio1.91x
Interest coverage—

Cash quality & payout

Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31
Income statement
Revenue—
Income tax$358,000
Net income-$13.45M
EPS (basic)-0.22
EPS (diluted)-0.22
Weighted avg. shares (diluted)60.73M
Balance sheet
Cash & equivalents$1.68M
Current assets$3.10M
PP&E, net$10,000
Goodwill$2.58M
Intangibles$2.50M
Total assets$8.30M
Current liabilities$799,000
Total liabilities$1.42M
Shareholders' equity$6.88M
Shares outstanding60.73M
Cash flow statement
Operating cash flow—
Stock-based compensation$624,000

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.